Bevacizumab and erlotinib: A promising new approach to the treatment of advanced NSCLC

Oncologist

Volumn 13, Issue 11, 2008, Pages 1166-1176

  Herbst, Roy S ^a   Sandler, Alan ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

EGFR; Erlotinib bevacizumab; NSCLC; VEGF

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ANTIBODY; TAXANE DERIVATIVE; VASCULOTROPIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEATH; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIDE EFFECT; TUMOR GROWTH; VEIN THROMBOSIS; WOUND DEHISCENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56749173617     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0108     Document Type: Review

References (85)

1. Parkin D, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. American Cancer Society: Cancer Facts & Figures 2004. 2005. Available at http://www.cancer.org/docroot/STT/stt_0_2004.asp?sitearea=SST&level=1. Accessed November 3, 2008.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer, V.1.2009. Available at http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf, accessed April 7, 2008.
4. Rosell R, Taron M, Ariza A et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004;31(suppl 1):20-27.
5. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
6. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
7. Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev Anticancer Ther 2003;3:435-442.
8. Socinski MA. Cytotoxic chemotherapy in advanced non-small cell lung cancer: A review of standard treatment paradigms. Clin Cancer Res 2004;10:4210s-4214s.
9. Taxotere® [prescribing information®. Bridgewater, NJ: Sanofi-Aventis.
10. Alimta® [prescribing information]. Indianapolis, IN: Eli Lilly and Company.
11. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-2555.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
13. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
14. Herbst RS, Fehrenbacher L, Belani CP et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-4750.
15. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
16. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36:127-137.
17. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-1225.
18. Fontanini G, Vignati S, Boldrini L et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861-865.
19. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
20. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
21. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
22. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
23. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
24. Manegold C, von Pawel J, Zatloukal P et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007;25(18 suppl):388s.
25. Manegold C, von Pawel J, Zatloukal P et al. BO17704 (AVAiL): A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann Oncol 2008;19(suppl 8):viii1.
26. Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
27. Greatens TM, Niehans GA, Rubins JB et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 1998;157:1093-1097.
28. Ohsaki Y, Tanno S, Fujita Y et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000;7:603-607.
29. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-643.
30. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
31. Arteaga CL. The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19(18 suppl):32S-40S.
32. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-250.
33. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(suppl 4):S9-S15.
34. Ciardiello F, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs 2002;11:755-768.
35. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
36. Tsao M, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
37. Hanna N, Lilenbaum R, Ansari R et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006;24:5253-5258.
38. Merck KGaA. Merck: Erbitux Phase III Study - FLEX Increases Overall Survival in First-line Treatment of Non-Small Cell Lung Cancer. Available at http://news.merck.de/emd/cc/newsrelease.nsf/d6db9bdc0c08af7ec1257243005130ee/ b829c2883d587ff4c1257352004ec0c5?opendocument. Accessed November 3, 2008.
39. ImClone Systems Inc. Data Available from Erbitux® Phase III Study in First-Line Treatment of Advanced Lung Cancer. Available at http://phx.corporate- ir.net/phoenix.zhtml?c=97689&p=irol-newsArticle&ID=1025428& highlight. Accessed November 3, 2008.
40. Lilenbaum R, Bonomi P, Ansari R et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results. J Clin Oncol 2005;23:7036.
41. Tarceva® [prescribing information]. Melville, NY: OSI Pharmaceuticals, Inc.
42. Tarceva® [European product information]. London: European Medicines Agency, 2006. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/ tarceva/H-618-PI.en.pdf. Accessed November 3, 2008.
43. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-2158.
44. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
45. Gefitinib (marketed as Iressa®) [patient information sheet]. Rockville, MD: U.S. Food and Drug Administration, 2005.
46. Niho S, Ichinose Y, Tamura T et al. Results of a randomized phase III study to compare the overall survival of gefitinib versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 2007;25(18 suppl):387s.
47. Douillard J-Y, Kim E, Hirsh V et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: A randomized, open-label Phase III study (INTEREST). J Thorac Oncol 2007;2(suppl 4):S305-S306.
48. Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: Factors influencing treatment selection. The Oncologist 2006;11:655-665.
49. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
50. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
51. Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. The Oncologist 2007;12:610-621.
52. Govindan R, Garfield DH. Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 2004;31(suppl 11):27-31.
53. Bunn PA Jr, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2003;95:341-343.
54. van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer 2005;117:883-888.
55. Camp ER, Summy J, Bauer TW et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005;11:397-405.
56. Jung YD, Mansfield PF, Akagi M et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-1140.
57. Ciardiello F, Bianco R, Damiano V et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-3747.
58. Shaheen RM, Ahmad SA, Liu W et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584-589.
59. Guy SP, Ashton SE, Hughes G et al. Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular-targeting agent ZD6126 in human colorectal cancer and non-small cell lung cancer (NSCLC) xenograft models. Clin Cancer Res 2003;9:B13.
60. Sandler A, Herbst R. Combining targeted agents: Blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 2006;12:4421s-4425s.
61. Groen HJ, Smit EF, Dingemans A. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:7625.
62. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 2005;23:LBA4.
63. Dowlati A. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24:7027.
64. Gatzemeier U, Heller A, Foernzler D et al. Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT). J Clin Oncol 2005;23:7028.
65. Miller VA, Herbst R, Prager D et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. J Clin Oncol 2004;23(14 suppl):628.
66. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
67. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
68. Tsao M, Zhu A, Sakurada T et al. An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR. 21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol 2006;24(18 suppl):7005.
69. Kris M, Sandler A, Miller V et al. Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). J Clin Oncol 2004;22(14 suppl):628.
70. Miller VA, Kris MG, Shah N et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-1109.
71. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-2246.
72. Clark GM, Zborowski D, Santabárbara P et al. Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression. J Clin Oncol 2005;23(16 suppl):628s.
73. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
74. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
75. Shigematsu H, Takahashi T, Nomura M et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642-1646.
76. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520.
77. Huang SF, Liu HP, Li LH et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-8203.
78. Gumerlock PH, Holland WS, Chen H et al. Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib. J Clin Oncol 2005;23(16 suppl):623s.
79. Miller VA, Zakowski M, Riely GJ et al. EGFR mutation, immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC. J Clin Oncol 2005;23(16 suppl):628s.
80. Takano T, Ohe Y, Yoshida T et al. Evaluation of epidermal growth factor receptor (EGFR) mutations and gene copy numbers as predictors of clinical outcomes in Japanese patients with recurrent non-small-cell lung cancer (NSCLC) receiving gefitinib. J Clin Oncol 2005;23(16 suppl):628s.
81. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
82. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792.
83. Natale R, Bodkin D, Govindan R et al. A comparison of the antitumor efficacy of ZD 6474 and gefitinib (Iressa) in patients with NSCLC: Results of a randomized, double-blind, phase II study. Lung Cancer 2005;49(suppl 2):S37.
84. Scagliotti G, von Pawel J, Reck M et al. Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): Interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC) trial. J Thorac Oncol 2008;3(suppl 1):S97.
85. Socinski MA. The current status and evolving role of sunitinib in non-small cell lung cancer. J Thorac Oncol 2008;3(suppl 2):S119-S123.